Schedule H

Oral

• Tablet: 5 mg

• Tablet: 10 mg

INDICATIONS + DOSING — FOR CLINICIAN USE ONLY

Primary Indications (Approved / Standard in India)

1. Hypertension (Essential, Mild-to-Moderate)

Parameter Recommendation

Starting dose 5 mg twice daily

Titration Increase by 5–10 mg/day at weekly intervals based on blood pressure response

Usual maintenance dose 15–30 mg/day in 2–3 divided doses

Maximum dose 60 mg/day

Key Clinical Notes:

• Due to intrinsic sympathomimetic activity (ISA), less likely to cause resting bradycardia or fatigue compared to beta-blockers without ISA

• Not the preferred beta-blocker for angina pectoris or post-myocardial infarction — lacks proven mortality benefit in these settings

• May be considered in patients intolerant to other beta-blockers due to fatigue or cold extremities

• Can be administered with or without food

1. Cardiac Arrhythmias (Supraventricular and Ventricular Ectopy)

Parameter Recommendation

Starting dose 2.5–5 mg twice daily

Titration Adjust according to arrhythmia frequency and clinical response

Usual maintenance dose 10–30 mg/day in divided doses

Maximum dose 60 mg/day

Key Clinical Notes:

• Use under cardiologist supervision for arrhythmias beyond benign ectopy

• Baseline and periodic ECG monitoring recommended

• Not first-line for sustained ventricular tachycardia or complex arrhythmias

Secondary Indications — Adults (Off-label)

Indication Dose Duration Notes Evidence Basis

Migraine Prophylaxis Starting: 5 mg twice daily; Maintenance: 5–10 mg twice daily Assess response after 8–12 weeks Specialist only; OFF-LABEL Beta-blocker class effect; propranolol generally preferred due to more robust evidence; consider pindolol if propranolol poorly tolerated

PAEDIATRIC DOSING (Specialist Only)

Primary Indications (Approved / Standard in India)

Not approved for routine paediatric use in India. Use only under paediatric cardiology supervision.

Secondary Indications — Paediatric (Off-label)

Arrhythmias or Hypertrophic Cardiomyopathy (Specialist Use Only; OFF-LABEL)

Parameter Recommendation

Starting dose 0.2 mg/kg/day in 2–3 divided doses

Titration Increase gradually based on clinical response and tolerance

Usual maintenance dose 0.2–0.5 mg/kg/day in 2–3 divided doses

Maximum dose 1 mg/kg/day OR 60 mg/day (whichever is lower)

Safety Monitoring:

• ECG monitoring at baseline and during dose titration

• Heart rate and blood pressure monitoring

• Blood glucose monitoring (especially in neonates and infants — risk of hypoglycaemia)

• Observe for signs of bradycardia, fatigue, or bronchospasm

Age Restrictions:

• Children <1 year: NOT recommended except under supervised inpatient care with paediatric cardiology oversight

• Limited Indian paediatric data available

• Mild Impairment (Child-Pugh A): No dose adjustment usually required

• Moderate Impairment (Child-Pugh B): Start at lower dose (2.5–5 mg twice daily); titrate cautiously with close monitoring

• Severe Impairment (Child-Pugh C): Avoid use or use only under specialist supervision with very cautious titration; hepatic metabolism may be significantly impaired

• Bronchial asthma or severe chronic obstructive pulmonary disease (COPD)

• Second or third degree atrioventricular block (without functioning pacemaker)

• Sick sinus syndrome (without pacemaker)

• Sinus bradycardia (resting heart rate <50 bpm)

• Decompensated or uncontrolled heart failure

• Cardiogenic shock

• Severe hypotension (systolic BP <90 mmHg)

• Untreated pheochromocytoma (unless adequate alpha-blockade established first)

• Known hypersensitivity to pindolol or other beta-blockers

• Concurrent use with intravenous verapamil or diltiazem

• Diabetes mellitus — may mask symptoms of hypoglycaemia (tachycardia, tremor); glucose monitoring advised

• Peripheral vascular disease — may worsen claudication symptoms

• Mild-to-moderate asthma or reactive airways — use with extreme caution; monitor closely for bronchospasm

• Thyrotoxicosis — may mask clinical signs; do not withdraw abruptly in thyroid storm

• Depression — beta-blockers may exacerbate; pindolol may have lower risk due to ISA

• First-degree heart block — monitor for progression

• Myasthenia gravis — may worsen symptoms

• Psoriasis — beta-blockers may exacerbate

• Abrupt withdrawal — avoid in cardiac patients; taper over 1–2 weeks to prevent rebound tachycardia, hypertension, or angina exacerbation

• General anaesthesia — inform anaesthetist; may require dose adjustment or temporary discontinuation

Parameter Details

Overall Safety Use only if potential benefit justifies fetal risk

Fetal Risks Bradycardia, hypoglycaemia, intrauterine growth restriction reported with beta-blockers

Preferred Alternatives Labetalol, methyldopa (standard Indian obstetric practice)

When May Be Used If alternatives contraindicated or ineffective; requires specialist input

Monitoring Fetal heart rate monitoring, serial growth scans, neonatal observation for bradycardia and hypoglycaemia post-delivery

Parameter Details

Compatibility Generally compatible with breastfeeding; low milk excretion

Drug Levels in Milk Low

Preferred Alternatives Labetalol, metoprolol (more safety data available in lactation)

Infant Monitoring Observe for bradycardia, poor feeding, irritability, lethargy

• Recommended starting dose: 2.5–5 mg twice daily

• Titration: Slow titration at 1–2 week intervals; assess tolerance before each increment

• Extra Risks:

• Increased sensitivity to hypotensive effects — risk of orthostatic hypotension and falls

• Higher prevalence of conduction abnormalities — monitor for bradycardia

• Reduced renal reserve — may affect drug clearance

• Cognitive effects (confusion, depression) — monitor during therapy

• May mask hypoglycaemia in diabetic elderly patients

Interacting Drug Mechanism / Effect Clinical Advice

Verapamil / Diltiazem Additive negative inotropic and chronotropic effects Avoid combination — risk of severe bradycardia, heart block, or cardiac failure

Clonidine Rebound hypertension if clonidine withdrawn while on beta-blocker If discontinuing both, taper beta-blocker first, then clonidine

MAO inhibitors Additive hypotensive effects; hypertensive crisis with tyramine-containing foods Avoid concurrent use

Adrenaline (epinephrine) Reduced response to adrenaline in anaphylaxis due to beta-blockade Higher adrenaline doses may be required; glucagon as alternative

Flecainide / Disopyramide Additive negative inotropic effect Avoid combination or use with extreme caution under specialist supervision

Interacting Drug Effect Recommendation

Insulin / Oral hypoglycaemics Masking of hypoglycaemia symptoms (except sweating) Monitor blood glucose more frequently; counsel patients

Digoxin Additive bradycardia and AV nodal suppression Monitor heart rate and ECG; consider dose adjustment

NSAIDs (ibuprofen, diclofenac) Blunted antihypertensive effect; fluid retention Monitor blood pressure; consider alternative analgesics

Rifampicin Enhanced hepatic metabolism of pindolol Monitor blood pressure; may need higher pindolol dose

Antipsychotics (chlorpromazine, haloperidol) Additive hypotensive effect Monitor blood pressure closely

Ergotamine Increased peripheral vasoconstriction Monitor for peripheral ischaemia

• Fatigue (less common than with non-ISA beta-blockers)

• Dizziness

• Headache

• Nausea, gastrointestinal discomfort

• Cold extremities (less common due to ISA)

• Sleep disturbances, vivid dreams (less than propranolol due to lower lipophilicity)

• Palpitations (may occur due to partial agonist activity)

• Mild dyspnoea on exertion

Adverse Effect Clinical Notes

Severe bradycardia May require temporary pacing; discontinue drug

Complete heart block Rare; requires immediate discontinuation and cardiology consultation

Bronchospasm May occur especially in patients with reactive airways; discontinue and treat urgently

Acute heart failure exacerbation Discontinue; manage with diuretics and specialist input

Severe hypotension IV fluids, consider inotropic support if needed

Hypersensitivity reactions / Anaphylaxis Rare; immediate discontinuation; standard anaphylaxis management

Long-term Periodic heart rate and blood pressure monitoring; annual ECG; blood glucose monitoring in diabetics; reassess need for therapy periodically

• Visken® (Novartis) — original brand; limited current availability

• Generic pindolol tablets — limited availability; may require procurement from specific distributors

Note: Pindolol has limited market availability in India compared to other beta-blockers (metoprolol, atenolol, propranolol). Availability should be confirmed locally before prescribing.

• Not included in NLEM 2022

• Not NPPA price-controlled

• Limited availability in both government and private sector pharmacies

• May need to be specially ordered

1. Unique ISA property: Pindolol causes less resting bradycardia and fatigue compared to beta-blockers without intrinsic sympathomimetic activity — may be better tolerated in patients experiencing these side effects with other agents.

1. Not for post-MI or heart failure: Unlike carvedilol, bisoprolol, or metoprolol succinate, pindolol lacks proven mortality benefit in post-MI or heart failure with reduced ejection fraction — avoid in these indications.

1. Cold extremities concern: May be better tolerated than non-ISA beta-blockers in patients with peripheral vascular symptoms; however, still use cautiously.

1. Avoid abrupt cessation: Particularly in patients with coronary artery disease — taper over 1–2 weeks to prevent rebound angina, arrhythmias, or hypertensive crisis.

1. Limited availability in India: Before prescribing, confirm local availability; metoprolol, atenolol, and propranolol are more readily accessible alternatives.

1. Hypoglycaemia masking: Particularly important in diabetic patients on insulin or sulfonylureas — counsel patients that sweating will still occur but tachycardia may be blunted.

pindolol; beta-blocker; ISA; hypertension; arrhythmia; non-selective; limited-availability-India; not-NLEM; not-for-post-MI; pregnancy-caution

RxIndia v1.0 — 10 Jun 2025

• CDSCO approved drug database

• Indian Pharmacopoeia

• National Formulary of India (NFI)

• NLEM 2022 (not listed)

• API Textbook of Medicine

• Goodman & Gilman's The Pharmacological Basis of Therapeutics

• AIIMS Drug Formulary

• Harrison's Principles of Internal Medicine